Notably, the increase of ERCC1 expression or of ATP7B and the loss of CTR1 have been all consistently reported as mechanisms of platinum resistance as well as predictors of poor response to platinum-based chemotherapy in cancer patients, including HNSCC (Bisof et al., 2016; Sun et al., 2017; Petruzzelli and Polishchuk, 2019). The gene discussed is ATP7B; the disease is cancer.